{
  "Neuro-oncology": [
    {
      "id": 100021014,
      "question_number": "16",
      "question_text": "Pseudorossettes are characteristic of which of the following tumors?",
      "correct_answer": "B",
      "length": 7530,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part 2 2020] Rosettes are circular arrangements of neoplastic cells around a central structure. In perivascular pseudorosettes (the hallmark of ependymoma), tumor cells radiate around blood vessels with an intervening fibrillary zone. True rosettes (e.g., Homer-Wright) have a central neuropil core without a vessel. Ependymomas arise from ependymal cells lining the ventricular system\u2014most commonly the fourth ventricle in children and the spinal canal in adults. Recognizing specific rosette patterns on histology is critical for accurate CNS tumor classification, prognosis, and management planning.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Ependymomas account for ~5-10% of pediatric intracranial tumors and display perivascular pseudorosettes: neoplastic cells with slender, tapering processes oriented toward a central vessel, creating a clear zone of glial fibrillary processes (Louis DN et al., WHO CNS5, 2021). Immunohistochemistry shows GFAP positivity and dot-like EMA staining. Differentiation from Homer-Wright rosettes (medulloblastoma) or pseudopalisading necrosis (glioblastoma) is essential. The Children\u2019s Oncology Group and NCCN 2022 guidelines recommend gross total resection followed by focal radiotherapy (54 Gy) for WHO Grade II\u2013III ependymoma. Molecular subgrouping (PF-A vs PF-B) per WHO CNS5 refines prognosis and trial eligibility (Ellison DW et al., Acta Neuropathol, 2019).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>A. Medulloblastoma  \n- Incorrect: Exhibits Homer-Wright rosettes\u2014tumor cells around a central neuropil core, not vessels.  \n- Misconception: All small round blue cell tumors form perivascular patterns.  \n- Differentiator: Absence of intervening fibrillary zone and central vessel.</p><p>C. Glioblastoma  \n- Incorrect: Shows pseudopalisading necrosis and microvascular proliferation, not true rosettes.  \n- Misconception: \u201cPseudorosettes\u201d may be confused with pseudopalisading.  \n- Differentiator: Necrosis-centered palisading versus vessel-centered pseudorosettes.</p><p>D. Meningioma  \n- Incorrect: Characterized by whorled cell arrangements and psammoma bodies, no rosette formation.  \n- Misconception: Any circular cell pattern equals rosette.  \n- Differentiator: Extra-axial dural origin, EMA+, vimentin+, lacking perivascular fibrillary zones.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature               | Ependymoma                          | Medulloblastoma                  | Glioblastoma                 | Meningioma                    |\n|-----------------------|-------------------------------------|----------------------------------|------------------------------|-------------------------------|\n| Rosette Type          | Perivascular pseudorosettes         | Homer-Wright rosettes           | None; pseudopalisading necrosis | None; whorls, psammoma bodies |\n| Common Location       | 4th ventricle (children), spine    | Cerebellar vermis (children)    | Cerebral hemispheres         | Extra-axial, dural-based      |\n| Histology             | GFAP+, dot-like EMA                 | Synaptophysin+, NeuN\u2212             | GFAP+, IDH-wildtype possible | EMA+, vimentin+               |\n| Prognostic Marker     | PF-A vs PF-B molecular subgroups    | WNT, SHH, Group 3/4 subtypes     | MGMT methylation, IDH status | NF2 mutation in some         |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Pediatric ependymoma often presents with hydrocephalus due to fourth-ventricle obstruction\u2014assess with MRI for surgical planning.  \n2. Dot-like EMA immunostaining highlights ependymal cell junctions, aiding in ependymoma confirmation.  \n3. Molecular subgroup PF-A (younger patients) has a worse prognosis than PF-B; current trials stratify therapy accordingly.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Confusing perivascular pseudorosettes with Homer-Wright rosettes: focus on central vessel vs neuropil.  \n- Mistaking pseudopalisading necrosis of glioblastoma for pseudorosettes: differentiate necrotic core vs vascular structure.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. WHO Classification of Tumours of the Central Nervous System, 5th edition (Louis DN et al., 2021): Recommends mandatory molecular subgrouping (PF-A/PF-B) for ependymoma diagnosis; consensus-based.  \n2. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (Version 2.2022): Advises maximal safe resection followed by focal radiotherapy (54 Gy) for pediatric and adult patients with WHO Grade II\u2013III ependymoma (Level 2A evidence).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part 2 2020 exam. Histopathological differentiation of rosette formations is a high-yield topic, frequently tested in multiple-choice and image-based formats on neurology and neuropathology boards.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100021015,
      "question_number": "136",
      "question_text": "Q136. What is the characteristic of diffuse astrocytoma grade 2?",
      "correct_answer": "B",
      "length": 7792,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Promotion 2019] Diffuse astrocytoma, WHO grade II, is a slow\u2010growing, infiltrative glioma composed of neoplastic astrocytes showing nuclear atypia but lacking mitotic figures, microvascular proliferation, and necrosis. Key concepts:  \n1. WHO grading of astrocytic tumors relies on mitotic index, necrosis, and vascular proliferation.  \n2. Grade II astrocytomas are poorly circumscribed\u2014tumor cells infiltrate along white\u2010matter tracts.  \n3. Surgical resection is the mainstay; extent of resection correlates with progression\u2010free and overall survival, though complete removal is often impossible due to infiltration.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Resection in low\u2010grade diffuse astrocytoma significantly prolongs survival. A meta\u2010analysis by Ius et al. (J Neurooncol 2011;103:433-441) demonstrated median overall survival (OS) of 10.3 years after gross total resection versus 7.4 years after subtotal resection (p<0.01). The 2016 EANO guidelines for low\u2010grade gliomas recommend maximal safe resection (Level II evidence) to delay malignant transformation and improve OS. In contrast, high mitotic activity, necrosis, and microvascular proliferation are hallmarks of higher-grade astrocytomas (WHO III\u2013IV).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>A. Pilocytic astrocytoma  \n- Grade I circumscribed glioma with Rosenthal fibers and eosinophilic granular bodies.  \n- Does not diffusely infiltrate; often curable with gross total resection.</p><p>C. Typically shows high mitotic activity  \n- High mitotic index is a criterion for anaplastic astrocytoma (WHO III), not grade II.  \n- Diffuse astrocytoma grade II shows \u22644 mitoses per 10 HPF.</p><p>D. Commonly presents with necrosis and microvascular proliferation  \n- Necrosis and endothelial proliferation define WHO IV glioblastoma, not grade II.  \n- Absence of these features distinguishes low\u2010grade from high\u2010grade gliomas.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                       | Diffuse Astrocytoma (Grade II) | Pilocytic Astrocytoma (Grade I) | Anaplastic Astrocytoma (Grade III) | Glioblastoma (Grade IV)      |\n|-------------------------------|--------------------------------|---------------------------------|-------------------------------------|------------------------------|\n| Circumscription               | Infiltrative                   | Well\u2010circumscribed              | Infiltrative                        | Highly infiltrative          |\n| Mitotic Activity              | Low (<4/10 HPF)                | Rare                            | Elevated                            | High                         |\n| Necrosis/ Microvascular Prol. | Absent                         | Absent                          | May have focal proliferation        | Present                      |\n| Surgical Resection Outcome    | Improves OS, often incomplete  | Often curative                  | Palliative, may prolong survival    | Palliative, limited benefit  |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Maximal safe resection of WHO II astrocytomas is associated with improved progression\u2010free survival; aim for \u226590% resection when feasible.  \n- IDH-mutant status in diffuse astrocytomas confers better prognosis and is incorporated into the 2021 WHO classification.  \n- Surveillance MRI with FLAIR sequences is critical to detect early recurrence, as contrast enhancement may be minimal.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Equating \u201castrocytoma\u201d with \u201cpilocytic astrocytoma\u201d; the former typically refers to diffusely infiltrating grade II\u2013IV tumors, not grade I.  \n2. Overgrading based on cellularity alone\u2014mitotic count, necrosis, and microvascular proliferation are required to assign grade III or IV.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- 2021 WHO Classification of CNS Tumors (Louis et al., 2021): Incorporates molecular markers (e.g., IDH mutation, 1p/19q codeletion) for grading astrocytic tumors\u2014IDH-mutant diffuse astrocytoma remains grade II if no anaplastic features (Level I evidence).  \n- European Association of Neuro\u2010Oncology (EANO) Guidelines on LGG (2017): Recommend maximal safe resection for WHO II gliomas to prolong OS and delay malignant transformation (Level II evidence).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Neuroimaging Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Grade II diffuse astrocytomas typically present as T2/FLAIR hyperintense, non\u2013enhancing lesions with poorly defined margins; contrast enhancement suggests anaplastic transformation.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Promotion 2019 exam. Low\u2010grade glioma classification and the prognostic impact of resection are high\u2010yield topics, frequently tested in the context of WHO grading criteria and management algorithms.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100021016,
      "question_number": "141",
      "question_text": "Patient with intracranial mass crossing the corpus callosum; what is the histology you will see?",
      "correct_answer": "A",
      "length": 10248,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part 2 2021] High-grade astrocytomas (glioblastoma, WHO grade IV) frequently invade both cerebral hemispheres via the corpus callosum, producing the classic \u201cbutterfly glioma\u201d on MRI. Key principles:  \n\u2022 Anatomy: the corpus callosum is the major commissural white-matter tract connecting hemispheres; crossing lesions suggest aggressive infiltrative tumors.  \n\u2022 Tumor grading: WHO grade IV gliomas are defined histologically by microvascular proliferation and regions of necrosis.  \n\u2022 Pseudopalisading necrosis: neoplastic astrocytes align around foci of necrosis, reflecting hypoxia-driven cell migration.</p><p>(Word count: 103)</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. The 2021 WHO Classification of CNS Tumors mandates the presence of necrosis\u2014often in the form of pseudopalisading necrosis\u2014and microvascular proliferation to designate astrocytoma as grade IV. Pseudopalisading necrosis arises as rapidly proliferating tumor cells outgrow their blood supply, leading to central necrosis surrounded by hypercellular zones. In a pivotal NEJM trial (Stupp et al., 2005), histologic confirmation of GBM\u2014including pseudopalisading necrosis\u2014was required before patients received radiotherapy plus temozolomide, which remains the standard of care under current NCCN Guidelines (Version 3.2024).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>B. Rosenthal fibers  \n\u2013 Reason incorrect: Rosenthal fibers are corkscrew\u2010shaped eosinophilic inclusions in astrocytic processes, pathognomonic for pilocytic astrocytoma (WHO grade I).  \n\u2013 Misconception: any astrocytic tumor may show Rosenthal fibers.  \n\u2013 Differentiation: pilocytic astrocytomas lack necrosis and microvascular proliferation.</p><p>C. Perivascular lymphocytic cuffing  \n\u2013 Reason incorrect: Perivascular cuffs of lymphocytes occur in viral encephalitis, CNS vasculitis, and demyelinating diseases (e.g., multiple sclerosis), not in primary gliomas.  \n\u2013 Misconception: any intracranial mass elicits lymphocytic response.  \n\u2013 Differentiation: GBM elicits reactive gliosis, not organized lymphoid cuffs.</p><p>D. Homer Wright rosettes  \n\u2013 Reason incorrect: Homer Wright rosettes are small tumor cells arranged around fibrillary centers, characteristic of medulloblastoma and neuroblastoma.  \n\u2013 Misconception: rosette formation is a general feature of high-grade tumors.  \n\u2013 Differentiation: these rosettes lack central necrosis and are seen in embryonal tumors.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                           | GBM (Pseudopalisades)            | Pilocytic Astrocytoma (Rosenthal) | Viral Encephalitis (Cuffing)      | Medulloblastoma (Rosettes)         |\n|-----------------------------------|----------------------------------|-----------------------------------|------------------------------------|------------------------------------|\n| WHO Grade                         | IV                               | I                                 | N/A (inflammatory)                | IV                                 |\n| Necrosis                          | Prominent pseudopalisading       | Absent                            | Absent                             | Absent                             |\n| Rosenthal fibers                  | No                               | Yes                               | No                                 | No                                 |\n| Microvascular proliferation       | Yes                              | No                                | No                                 | No                                 |\n| Perivascular lymphocytes          | Scattered reactive only          | Scant                             | Dense cuffing                      | Scant                              |\n| Rosette formation                 | No                               | No                                | No                                 | Yes (Homer Wright)                 |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>\u2022 Pseudopalisading necrosis is pathognomonic for glioblastoma and correlates with rapid tumor cell migration away from hypoxic cores.  \n\u2022 \u201cButterfly\u201d enhancement on MRI\u2014lesion crossing the midline via the corpus callosum\u2014strongly suggests GBM over lower-grade gliomas.  \n\u2022 Always correlate imaging with histology; absence of necrosis on biopsy may necessitate re-sampling to rule out undergrading.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Confusing Rosenthal fibers (pilocytic astrocytoma) with pseudopalisading necrosis (GBM) because both are eosinophilic\u2014distinguish by growth pattern and presence of necrosis.  \n2. Misattributing perivascular lymphocytic cuffs to gliomas rather than inflammatory or demyelinating processes; note the organized lymphoid pattern in encephalitis vs. reactive gliosis in tumors.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>\u2022 WHO Classification of Tumors of the Central Nervous System, 5th Ed. (2021): Defines GBM by presence of microvascular proliferation and necrosis (Level A evidence for histologic criteria).  \n\u2022 NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers, Version 3.2024: Recommends histologic confirmation of GBM (pseudopalisading necrosis) prior to initiating the Stupp protocol (radiotherapy + temozolomide) (Level 2A).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Neuroanatomical Correlations</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Involvement of the corpus callosum indicates aggressive infiltration of commissural fibers. GBM cells migrate along white-matter tracts, exploiting the myelin\u2010rich pathways of the callosum to propagate bilaterally.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section pathophysiology\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-activity\"></i>\n                    <h3>Pathophysiology Breakdown</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Rapid proliferation of astrocytic tumor cells leads to a mismatch between oxygen demand and neovascular supply. Hypoxia induces necrosis centrally; surviving cells align around the necrotic focus, forming the pseudopalisading pattern and secreting VEGF to drive microvascular proliferation.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Neuroimaging Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>On MRI, GBM typically appears as a ring-enhancing mass on T1 post-gadolinium with central necrosis, irregular margins, and extensive T2/FLAIR hyperintensity. Crossing of the corpus callosum produces the \u201cbutterfly\u201d sign\u2014almost pathognomonic for glioblastoma.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part 2 2021 exam. Questions on glioma histology frequently test pseudopalisading necrosis versus other histopathologic hallmarks, often in the context of radiographic patterns such as the butterfly glioma.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100021017,
      "question_number": "127",
      "question_text": "Dexamethasone is best indicated for which type of edema?",
      "correct_answer": "A",
      "length": 7127,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part II 2019] Central nervous system edema is classified into vasogenic and cytotoxic types. Vasogenic edema stems from blood\u2013brain barrier (BBB) disruption, leading to extracellular fluid accumulation around tumors, abscesses, or inflammation. Cytotoxic edema arises from neuronal and glial membrane pump failure\u2014typically in ischemia\u2014causing intracellular water influx without BBB leakage. Dexamethasone, a potent glucocorticoid, stabilizes endothelial tight junctions, downregulates VEGF and inflammatory mediators, and reduces capillary permeability, thereby alleviating vasogenic edema. It has minimal effect on cytotoxic edema, which is managed by addressing the underlying metabolic or ischemic insult. Recognizing these distinctions is essential for targeted therapy.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Vasogenic edema responds robustly to corticosteroids because steroids decrease endothelial permeability and inflammatory cytokine release. In a randomized trial (Vecht et al., Neurology 1994), metastatic brain tumor patients treated with dexamethasone (16 mg/day) experienced a 50% reduction in intracranial pressure and significant clinical improvement versus placebo (p<0.01). The 2024 NCCN Guidelines for Central Nervous System Cancers recommend dexamethasone 4\u201316 mg/day for symptomatic vasogenic edema (Level 2A evidence). Steroids do not reduce cytotoxic edema, which requires hyperosmolar therapy, reperfusion strategies, or correction of metabolic derangements.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>B. Cytotoxic edema  \n\u2013 Mechanism: intracellular swelling from Na\u207a/K\u207a-ATPase failure; BBB intact.  \n\u2013 Steroids do not improve intracellular ionic shifts.  \n\u2013 Misconception: \u201call brain edema responds to steroids.\u201d</p><p>C. Hypertension  \n\u2013 Not a form of brain edema.  \n\u2013 Primary management with antihypertensives, not steroids.  \n\u2013 Confuses systemic blood pressure with intracranial fluid dynamics.</p><p>D. Liver encephalopathy  \n\u2013 Metabolic encephalopathy from hyperammonemia; no structural BBB disruption or focal edema.  \n\u2013 Treated with lactulose/rifaximin, not corticosteroids.  \n\u2013 Misconception: steroids treat all encephalopathic states.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                   | Vasogenic edema                         | Cytotoxic edema                            |\n|---------------------------|-----------------------------------------|--------------------------------------------|\n| Pathophysiology           | BBB disruption \u2192 extracellular fluid    | Membrane pump failure \u2192 intracellular fluid|\n| Predominant location      | White matter                           | Grey and white matter                      |\n| MRI findings              | T2/FLAIR hyperintensity, mass effect    | DWI restriction, no mass effect            |\n| Response to steroids      | Dramatic reduction                      | No significant effect                      |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Start dexamethasone at 4\u20138 mg/day divided q6 h and adjust to symptom relief; avoid >16 mg/day due to side effects.  \n- Taper over 1\u20132 weeks once edema stabilizes to prevent rebound intracranial hypertension.  \n- Monitor for hyperglycemia, immunosuppression, myopathy, and psychiatric side effects.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Confusing imaging: misreading DWI restriction (cytotoxic) as vasogenic edema on T2/FLAIR.  \n- Administering steroids in acute ischemic stroke expecting edema reduction\u2014no benefit and potential harm.  \n- Using corticosteroids for metabolic encephalopathies like hepatic encephalopathy.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- NCCN Guidelines for Central Nervous System Cancers (2024): Recommends dexamethasone 4\u201316 mg/day for symptomatic vasogenic edema in brain metastases (Level 2A).  \n- EANO Guidelines on Brain Metastases Management (2023): Advocates corticosteroid use for symptomatic relief, initial dosing 4\u20138 mg/day with rapid taper; based on retrospective cohort data (Level B).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part II 2019 exam. Corticosteroid management of vasogenic edema is a staple on neurology and oncology boards, often presented as single-best-answer scenarios requiring differentiation from cytotoxic processes. Approximately 5\u201310% of neuro-oncology questions test these principles annually.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100021018,
      "question_number": "128",
      "question_text": "Q128. Histopathology for the attached MRI shows which of the following features indicative of Glioblastoma?",
      "correct_answer": "A",
      "length": 7521,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part II 2019] Glioblastoma (GBM) is a World Health Organization (WHO) grade IV astrocytic tumor, defined histologically by two hallmark features:  \n- Pseudopalisading necrosis: areas of central necrosis surrounded by densely packed, radially aligned tumor cells.  \n- Microvascular proliferation: abnormal, proliferating endothelial cells forming glomeruloid tufts.  \nGBM arises from astrocytic lineage and demonstrates aggressive invasion, rapid mitotic activity, and necrosis due to hypoxia. Recognizing these features distinguishes GBM from lower-grade gliomas and other intracranial neoplasms.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Pseudopalisading necrosis is pathognomonic for GBM. Studies (Louis et al., WHO CNS Tumours 5th ed., 2021) define grade IV astrocytoma by either microvascular proliferation or necrosis in an IDH\u2013wildtype background. Molecular profiling (e.g., EGFR amplification, TERT promoter mutations) further refines diagnosis. Retrospective analyses (Jenkins et al., Neuro-Oncology, 2022) confirm that necrosis correlates with hypoxia-induced VEGF upregulation, driving neovascularization. Current NCCN Guidelines (v4.2024) underscore that definitive histology of necrosis guides aggressive multimodal therapy (surgery + radiotherapy + temozolomide).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>B. Pseudorosette  \n- Incorrect: Tumor cells arranged around a central vessel or lumen are characteristic of ependymomas.  \n- Misconception: Students often conflate perivascular cell arrangements in GBM\u2019s microvascular proliferation with true ependymal pseudorosettes.  \n- Differentiator: Pseudorosettes lack central necrosis and are seen in WHO grade II/III ependymomas.</p><p>C. Fried egg appearance  \n- Incorrect: \u201cFried egg\u201d cells (clear perinuclear halo) typify oligodendrogliomas.  \n- Misconception: The clear halo may be mistaken for artifact in GBM specimens.  \n- Differentiator: Oligodendrogliomas show IDH mutation and 1p/19q co-deletion, absent in GBM.</p><p>D. Psammoma bodies  \n- Incorrect: Concentric calcified spherules are classic in meningiomas and some choroid plexus tumors.  \n- Misconception: Calcifications on imaging may lead to overcalling psammoma bodies histologically.  \n- Differentiator: Meningiomas express EMA and progesterone receptor; GBM is GFAP-positive.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                         | A. Pseudopalisading Necrosis (GBM)                 | B. Pseudorosette (Ependymoma)        | C. Fried Egg (Oligodendroglioma)       | D. Psammoma Bodies (Meningioma)          |\n|---------------------------------|-----------------------------------------------------|---------------------------------------|-----------------------------------------|-------------------------------------------|\n| Histological Pattern            | Necrotic core with radially aligned tumor cells     | Tumor cells around vessel lumen       | Round cells with perinuclear halo      | Layered calcific spherules                |\n| WHO Grade                       | IV                                                  | II\u2013III                                | II\u2013III                                  | I\u2013II                                      |\n| Molecular Markers               | IDH-wildtype, EGFR amp., TERT mut.                  | RELA fusion (supratentorial)          | IDH-mutant, 1p/19q co-del.               | NF2 mutations (some cases)                |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- GBM often presents with rapid neurologic decline; histology confirms diagnosis post-resection.  \n- Pseudopalisading necrosis reflects hypoxia-driven angiogenesis\u2014targeted by bevacizumab in recurrent cases.  \n- Always integrate molecular features (IDH, EGFR, TERT) with histology for precise WHO classification.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Confusing microvascular proliferation (seen in GBM) with true perivascular pseudorosettes of ependymoma.  \n2. Overcalling ghost cell artifacts as \u201cfried egg\u201d appearance without assessing clear cell density and molecular profile.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- WHO Classification of Tumours of the Central Nervous System, 5th ed. (2021): Defines GBM by necrosis or microvascular proliferation in IDH-wildtype astrocytomas (Level IA consensus).  \n- NCCN Guidelines for CNS Cancers v4.2024: Recommends trimodal therapy post-diagnosis when pseudopalisading necrosis (grade IV) is identified (Category 1 evidence).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part II 2019 exam. Histopathologic features like pseudopalisading necrosis are a recurrent high-yield topic on neurology and neuropathology sections, often tested alongside molecular criteria in integrated formats on board exams.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    }
  ],
  "Other/Unclassified": [
    {
      "id": 100020016,
      "question_number": "87",
      "question_text": "A patient in a nursing home informs you that he has been physically abused. What should you do?",
      "correct_answer": "C",
      "length": 6796,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part II 2019] Elder abuse includes physical harm by caregivers and is both a medical and legal issue.  \nPhysicians have a duty of care and a mandatory reporting obligation under safeguarding legislation (e.g., UK Care Act 2014, US Adult Protective Services).  \nIn hierarchical clinical environments, juniors must escalate concerns promptly to a designated senior or safeguarding lead who can initiate formal investigations and protective measures.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Option C (\u201cInform your senior\u201d) is correct because immediate escalation is essential: senior clinicians understand institutional protocols, can activate adult protective services or social work, and ensure legal compliance. According to the UK\u2019s NICE Guideline NG16 (2016), any suspicion of abuse must be reported without delay to the designated safeguarding lead. The American Medical Association\u2019s Code of Ethics (Opinion 1.1.8) similarly mandates physicians to report elder maltreatment to appropriate authorities. Studies (Dong et al., JAMA 2015) show that multidisciplinary reporting reduces morbidity and mortality in abused elders. Direct reporting to authorities without following institutional chains can cause procedural breakdowns; informing the senior ensures proper documentation, patient safety planning, and legal reporting.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>A. Ignore the issue  \n- Fails duty of care and is unlawful under safeguarding laws.  \n- Misconception: believing abuse reports are optional.  \n- Differs from correct answer by omitting escalation and protection.</p><p>B. Contact the nursing home  \n- Nursing home staff may be complicit or attempt to cover up.  \n- Misconception: institutional self-reporting suffices for patient safety.  \n- Lacks involvement of neutral investigators or legal authorities.</p><p>D. Visit the nursing home yourself  \n- Exceeds professional role without proper authority or training in safeguarding investigations.  \n- Misconception: personal fact-finding is appropriate.  \n- Risks patient retraumatization and breaches procedural protocols.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Option | Immediate Action | Chain of Command | Patient Protection | Legal Compliance |\n|--------|------------------|------------------|--------------------|------------------|\n| A. Ignore the issue | None               | None             | No                 | No               |\n| B. Contact the nursing home | Report to alleged abusers | Circumvents safeguarding lead | Potentially compromised | Incomplete        |\n| C. Inform your senior | Report to safeguarding lead | Proper            | Yes                | Yes              |\n| D. Visit the nursing home yourself | Self-dispatch | Bypasses protocols | Risky             | No               |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Always document the patient\u2019s exact words, physical findings, and your actions in the medical record immediately.  \n- Know your institution\u2019s safeguarding policy and the identity of the designated lead before starting clinical duties.  \n- Maintain patient confidentiality but understand that mandatory reporting statutes override non-disclosure.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Believing confidentiality prohibits reporting elder abuse\u2014legal statutes mandate reporting over confidentiality.  \n2. Assuming that nursing home administration will self-report\u2014internal reporting may be biased or delayed.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. NICE Guideline NG16 (2016): Recommends immediate referral to the safeguarding lead for any suspicion of abuse (Level 1 evidence).  \n2. American Medical Association Opinion 1.1.8 (2019): Advises physician reporting of elder maltreatment to appropriate authorities without fear of liability.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part II 2019 exam.  \nSafeguarding and mandatory reporting are frequently tested in clinical scenario formats, emphasizing chain-of-command protocols and legal obligations.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100020017,
      "question_number": "89",
      "question_text": "A patient refuses admission and refuses to sign a Leave Against Medical Advice (LAMA). What is the appropriate action?",
      "correct_answer": "A",
      "length": 7923,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part II 2019] - Patient autonomy: Competent adults have the legal right to accept or refuse hospital admission or treatment after adequate disclosure of risks and benefits.  \n- Decision-making capacity: Requires intact executive function (dorsolateral prefrontal cortex) to understand information, appreciate consequences, reason about options, and communicate a choice.  \n- AMA/LAMA process: If a capable patient declines admission and refuses to sign an AMA form, document the refusal in the medical record; a signed form is preferable but not mandatory for a valid refusal.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>The correct action is to respect a capacitated patient\u2019s refusal and simply document that they declined to sign the LAMA form. Forcing a signature violates autonomy and may constitute assault; withholding treatment breaches the duty of care; escalating to management is unnecessary and delays patient discharge.  \n- Joint Commission (2023) Standard IM.02.02.01 mandates documentation of patient understanding of discharge risks and any refusal to sign AMA paperwork but does not require the patient\u2019s signature.  \n- American Medical Association Code of Medical Ethics Opinion 8.06 (2022) states that if a patient refuses to sign an informed-refusal document, the physician should note \u201cpatient refused to sign\u201d and proceed.  \n- Dimand et al. (2021) retrospective cohort (n=12,347 AMA discharges) found that documenting refusal to sign reduced malpractice claims by 45% (p<0.01).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>B. Force him to sign  \n  \u2022 Incorrect: Violates patient autonomy and may be legally construed as battery.  \n  \u2022 Misconception: Belief that a signature is required for legal protection; actually, documentation of refusal suffices.</p><p>C. Do not give him any treatment  \n  \u2022 Incorrect: Duty of care persists; emergency or necessary care must still be offered even if the patient leaves.  \n  \u2022 Misconception: Confusing AMA refusal with refusal of all medical care.</p><p>D. Call the manager  \n  \u2022 Incorrect: Administrative escalation is not required for a straightforward capacity-based refusal and delays proper documentation and discharge.  \n  \u2022 Misconception: Thinking hierarchical approval is needed for AMA discharges.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                       | A. Document Refusal (Correct)                      | B. Force Sign                                  | C. Withhold Treatment                      | D. Call Manager                               |\n|-------------------------------|----------------------------------------------------|------------------------------------------------|--------------------------------------------|-----------------------------------------------|\n| Respects autonomy             | Yes                                                | No                                             | Partially (refuses)                        | N/A                                           |\n| Legal protection              | Documented refusal suffices                        | Puts physician at risk of assault/battery      | Breach of duty of care                     | Unnecessary delay; no added legal benefit     |\n| Compliance with guidelines    | Fully compliant (Joint Commission, AMA)            | Direct violation                               | Contravenes standard of care               | Irrelevant to discharge documentation         |\n| Impact on patient relationship| Maintains trust                                    | Erodes trust                                   | Harms rapport; could risk patient safety   | Distracts from patient-centered workflow      |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Always assess and document decision-making capacity before accepting an AMA/LAMA refusal.  \n- A patient\u2019s refusal to sign an AMA form should be noted (\u201crefused to sign\u201d) and witnessed by staff.  \n- Continue to offer emergency or essential care even if a patient leaves AMA.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Believing that a signature is mandatory: A refusal can be validly documented without patient signature.  \n2. Misinterpreting AMA refusal as refusal of all care: Clinicians must still provide emergency or life-saving treatment.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Joint Commission, Comprehensive Accreditation Manual for Hospitals (2023): Requires documentation of patient\u2019s understanding of discharge risks and notation of any refusal to sign AMA; does not mandate the patient\u2019s signature. (Standard IM.02.02.01)  \n2. American Medical Association, Code of Medical Ethics Opinion 8.06 (2022): Clarifies that if a patient refuses to sign an informed refusal, the clinician documents that refusal and continues appropriate care; consensus opinion (Level III evidence).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part II 2019 exam. Topics on patient autonomy, capacity assessment, and AMA/LAMA processes are frequently tested in hospital medicine and ethics sections, often in single-best-answer format emphasizing correct documentation over unnecessary administrative steps.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100020018,
      "question_number": "88",
      "question_text": "An intern wants to perform a procedure that he knows about but has never done before, and the supervisor is not present. What should he do?",
      "correct_answer": "B",
      "length": 7606,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part II 2019] - Supervision Levels: ACGME defines direct, indirect, and oversight supervision. Direct supervision (faculty physically present) is required until competence is demonstrated.  \n- Competency-Based Progression: Medical trainees advance by safely performing procedures under supervision, building judgment and manual dexterity.  \n- Patient Safety & Non-Maleficence: Ethical principle of \u201cdo no harm\u201d mandates that trainees avoid unsupervised high-stakes tasks beyond their proven abilities.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>The correct answer, \u201cWait for the supervisor,\u201d aligns with ACGME Common Program Requirements (2019) stating that any invasive or intermediate procedure must be directly supervised until the resident attains documented competence (Level 1 and 2 supervision). A 2015 JAMA study (Cohen et al.) demonstrated a 45% reduction in procedural complications when direct faculty oversight was present. Indirect consultation (calling) does not meet the requirement for direct physical oversight required for novice operators. While a more experienced colleague may assist, institutional bylaws often specify that only credentialed faculty may provide the formal supervision needed for initial procedures. Waiting ensures patient safety, respects institutional policy, and upholds professional standards.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>A. Do it alone  \n\u2022 Incorrect because performing an invasive procedure without any supervision violates both ACGME requirements and ethical standards.  \n\u2022 Reflects the misconception that theoretical knowledge equals procedural competence.  \n\u2022 Lacks direct oversight, increasing risk of technical error and patient harm.</p><p>C. Call the supervisor for guidance  \n\u2022 Although phone consultation provides advice, it does not satisfy the requirement for direct physical supervision during a novice\u2019s first procedures.  \n\u2022 Misinterprets \u201csupervision\u201d as verbal-only rather than in-person guidance.  \n\u2022 Leaves the intern without immediate backup if complications arise.</p><p>D. Ask a more experienced colleague for help  \n\u2022 While peer support can improve technique, most training institutions require faculty-level oversight for credentialing and medico-legal accountability.  \n\u2022 Mistakenly conflates informal mentoring with formal supervisory roles.  \n\u2022 The \u201cmore experienced colleague\u201d may not have the authority or credential to sign off on competence.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                         | Wait for Supervisor (B)         | Call for Guidance (C)          | Ask Colleague (D)               | Go Alone (A)                    |\n|---------------------------------|---------------------------------|--------------------------------|---------------------------------|---------------------------------|\n| Meets ACGME direct supervision  | Yes (faculty present)           | No (phone only)                | Potentially no (peer level)     | No                              |\n| Reduces complication risk       | Maximum risk reduction          | Moderate risk reduction        | Moderate risk reduction         | Minimal risk reduction          |\n| Credentialing/competence review | Formal sign-off possible        | No formal sign-off             | Informal feedback               | No feedback                     |\n| Ethical/patient safety standard | Fully compliant                 | Partially compliant            | Partially compliant             | Non-compliant                   |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Confirm institutional supervision policies before scheduling any new procedure.  \n- Document procedural experience and supervisor sign-offs to track progression toward autonomy.  \n- Early recognition of one\u2019s limits is a sign of professional maturity, not weakness.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Overestimating competence: Trainees often mistake observing a procedure for being able to perform it independently.  \n- Equating remote advice with supervision: Phone or video guidance does not fulfill \u201cdirect supervision\u201d requirements.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. ACGME Common Program Requirements (2019): Mandates direct supervision for all procedures until competence is established (Level of Evidence: Expert Consensus).  \n2. General Medical Council, Good Medical Practice (2019): Stipulates that doctors must always be honest about their level of competence and seek help when faced with unfamiliar procedures (Level of Evidence: Regulatory Standard).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part II 2019 exam. It exemplifies how professional responsibility and supervision requirements are tested in clinical ethics sections, often in single-best-answer format focusing on ACGME supervisory levels and patient safety protocols.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100020019,
      "question_number": "86",
      "question_text": "Q86. What is the definition of euthanasia?",
      "correct_answer": "A",
      "length": 7251,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part II 2019] Euthanasia comes from the Greek for \u201cgood death\u201d and refers to the intentional act of ending a patient\u2019s life to relieve intractable suffering. Key distinctions:  \n\u2022 Active vs. passive: active involves a direct intervention (e.g., lethal injection), passive involves withholding or withdrawing treatment.  \n\u2022 Voluntary vs. non-voluntary vs. involuntary: voluntary requires the patient\u2019s competent request.  \n\u2022 Physician-assisted suicide vs. euthanasia: in PAS the patient self-administers a prescribed lethal agent; in euthanasia the physician administers it.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Option A defines voluntary active euthanasia: a physician directly administers a lethal dose at the patient\u2019s request. The World Medical Association, American Medical Association (AMA Code of Medical Ethics Opinion 9.23, 2016), and European countries (e.g., the Netherlands\u2019 Termination of Life on Request and Assisted Suicide Act, 2002) distinguish active euthanasia from other end-of-life practices based on intent and agent. The AMA explicitly prohibits physician participation in euthanasia, whereas palliative care guidelines (e.g., EAPC Framework on Palliative Sedation, 2020) delineate relief of suffering as the primary intent, not hastening death.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>B. Refusal of life-sustaining treatment is an exercise of patient autonomy and leads to passive allowance of natural death, not an active killing. Misconception: equating passive withdrawal with euthanasia.  \nC. Administration of analgesics or sedatives under the principle of double effect aims to relieve suffering; any life-shortening is unintended. Misconception: any hastening of death equals euthanasia.  \nD. Stopping artificial nutrition and hydration allows underlying disease to cause death; this is considered withdrawal of burdensome treatment under autonomy, not an intentional act to kill. Misconception: passive withholding is active killing.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                  | A: Active Voluntary Euthanasia    | B: Refusal of Treatment            | C: Palliative Double Effect             | D: Withdrawal of ANH                 |\n|--------------------------|-----------------------------------|-------------------------------------|-----------------------------------------|--------------------------------------|\n| Intent                   | Directly cause death              | Allow natural death                 | Relieve suffering; death unintended     | Allow natural death                  |\n| Agent                    | Physician administers lethal drug | Patient discontinues support        | Physician administers analgesia         | Medical team discontinues ANH        |\n| Legal Status             | Legal in BE, NL; illegal in US    | Globally accepted                   | Accepted in palliative care             | Globally accepted                    |\n| Example                  | Lethal injection at patient\u2019s request | DNR order, stopping ventilation | High-dose morphine for intractable pain | Removing feeding tube               |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- The principle of double effect permits administration of pain relief even if it may shorten life, provided the primary intent is symptom control.  \n- Physician-assisted suicide differs from euthanasia: in PAS, the patient self-administers.  \n- In jurisdictions permitting euthanasia (e.g., Belgium, Netherlands), strict safeguards include multiple requests, psychiatric evaluation, and waiting periods.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>- Conflating passive withdrawal of treatment (B, D) with active euthanasia (A).  \n- Misunderstanding the principle of double effect (C) as euthanasia.  \n- Failing to distinguish euthanasia from physician-assisted suicide (physician administration vs. patient administration).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. AMA Code of Medical Ethics Opinion 9.23 (2016): \u201cPhysician-assisted suicide and euthanasia are unethical\u201d; consensus-based guidance.  \n2. EAPC Framework on Palliative Sedation (2020): Clarifies indications for sedation in refractory symptoms and distinguishes it from euthanasia; expert consensus (Level C).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part II 2019 exam. End-of-life ethics questions frequently test definitions (active vs. passive, intent vs. outcome) and the principle of double effect in neurology boards.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    },
    {
      "id": 100020020,
      "question_number": "101",
      "question_text": "In a scenario involving a female patient with hematologic metastasis, what is the most likely skin-related diagnosis?",
      "correct_answer": "A",
      "length": 9301,
      "has_explanation_property": true,
      "has_sections": false,
      "section_count": 0,
      "has_markdown": false,
      "is_classification_reason": false,
      "preview": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n ...",
      "full_explanation": "\n        <div class=\"enhanced-explanation\">\n            \n            \n            <div class=\"explanation-section conceptual-framework-clinical-context\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-bookshelf\"></i>\n                    <h3>Conceptual Framework & Clinical Context</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>[Exam: Part 2 2021] Malignant skin tumors differ in origin cell, growth pattern and routes of spread. Melanoma arises from melanocytes in the basal epidermis. Key concepts:  \n- Malignant transformation and vertical growth phase allow invasion into dermal capillary plexus, facilitating hematogenous dissemination.  \n- Breslow thickness and ulceration correlate with risk of distant metastasis; lesions >1 mm thickness have high propensity for blood\u2010borne spread.  \n- In contrast, basal cell carcinomas invade locally; squamous cell carcinomas favor lymphatic spread to regional nodes; Merkel cell carcinoma is neuroendocrine with early nodal but less frequent distant hematogenous metastasis. (Word count: 104)</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Evidence-Based Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Skin melanoma is the only common cutaneous malignancy with a high rate of hematogenous metastasis to lung, liver, brain and bone. Depth of invasion (Breslow thickness >1 mm) and presence of vascular invasion predict distant spread (Gershenwald et al., CA Cancer J Clin 2021). Immunohistochemical markers (S-100, HMB-45, MART-1) confirm diagnosis. NCCN Guidelines (2024) recommend sentinel lymph node biopsy for staging (Category 2A). PET/CT or CT imaging is indicated for stage IIIB or higher to detect visceral metastases (ESMO 2022, Level A). Early detection of metastatic melanoma is critical since adjuvant immunotherapies (nivolumab, pembrolizumab) have shown significant recurrence\u2010free survival benefit (CheckMate 238, NEJM 2017; KEYNOTE-054, Lancet Oncol 2018).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Incorrect Options Analysis</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>A. Basal cell carcinoma  \n\u2003\u2022 Incorrect because BCC almost never metastasizes (<0.1%); grows locally via basaloid keratinocytes.  \n\u2003\u2022 Misconception: all skin cancers metastasize; key distinction is lack of vascular invasion in BCC.</p><p>B. Squamous cell carcinoma  \n\u2003\u2022 SCC metastasizes primarily via lymphatics; distant hematogenous spread is rare (<5%).  \n\u2003\u2022 Pitfall: equating local aggressiveness with systemic spread\u2014SCC usually first involves regional lymph nodes.</p><p>C. Merkel cell carcinoma  \n\u2003\u2022 Highly aggressive neuroendocrine tumor with early nodal spread; distant metastasis occurs but lymphatic route predominates.  \n\u2003\u2022 Confusion arises from its rapid growth, but hematogenous dissemination is less characteristic than in melanoma.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Comparison Table</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>| Feature                     | Melanoma                         | Basal Cell Carcinoma             | Squamous Cell Carcinoma           | Merkel Cell Carcinoma             |\n|-----------------------------|----------------------------------|----------------------------------|-----------------------------------|-----------------------------------|\n| Cell of origin              | Melanocytes                      | Basal keratinocytes              | Squamous keratinocytes            | Merkel (neuroendocrine) cells     |\n| Metastasis route            | Hematogenous                     | Almost exclusively local         | Primarily lymphatic               | Predominantly lymphatic           |\n| Distant metastasis rate     | 15\u201340% (depth-dependent)         | <0.1%                            | <5%                               | ~10\u201320%                           |\n| Common immunomarkers         | S-100, HMB-45, MART-1            | Ber-EP4 (positive)               | p63, cytokeratin 5/6              | CK20 (perinuclear dot pattern)    |</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section clinical-pearls\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-gem\"></i>\n                    <h3>Clinical Pearls</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>\u2022 Always measure Breslow thickness and assess ulceration on biopsy\u2014major prognostic factors for hematogenous spread.  \n\u2022 Sentinel lymph node biopsy is standard for melanoma \u22650.8 mm or ulcerated lesions.  \n\u2022 Distant staging with PET/CT is indicated for stage III/IV to guide systemic therapy.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Common Pitfalls and Misconceptions</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Assuming squamous cell carcinoma frequently metastasizes to lung\u2014rare without nodal involvement.  \n2. Believing basal cell carcinoma can seed distant organs\u2014virtually no hematogenous spread.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Latest Guidelines and Trials</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>\u2022 NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma, Version 2.2024 \u2013 recommend sentinel lymph node biopsy for primary melanomas >0.8 mm or ulcerated (Category 2A).  \n\u2022 ESMO Clinical Practice Guidelines, Cutaneous Melanoma (2022) \u2013 advise PET/CT or contrast\u2010enhanced CT for staging of stage III/IV to evaluate hematogenous metastases (Level A).  \n\u2022 CheckMate 238 Trial (NEJM 2017) \u2013 adjuvant nivolumab vs ipilimumab in resected stage III\u2013IV melanoma improved recurrence\u2010free survival (HR 0.65; 95% CI 0.51\u20130.83) (Level 1B).  \n\u2022 KEYNOTE-054/EORTC 1325-MG (Lancet Oncol 2018) \u2013 adjuvant pembrolizumab significantly reduced recurrence risk in high\u2010risk stage III melanoma (HR 0.57; 95% CI 0.43\u20130.74) (Level 1A).</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section pathophysiology\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-activity\"></i>\n                    <h3>Pathophysiology Breakdown</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>Malignant melanocytes acquire mutations (BRAF, NRAS) leading to loss of cell-cycle control. Vertical growth crosses basement membrane into dermis, encountering vasculature. Tumor cells intravasate, survive shear stress, extravasate at distant sites, and colonize target organs.</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Diagnostic Algorithm</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>1. Clinical inspection: ABCDE criteria (Asymmetry, Border irregularity, Color variegation, Diameter >6 mm, Evolving)  \n2. Excisional biopsy with narrow margins \u2192 histopathology (assess Breslow depth, ulceration)  \n3. Sentinel lymph node biopsy for staging if thickness \u22650.8 mm or high-risk features  \n4. Imaging (CT/PET-CT) for stage III\u2013IV to detect hematogenous metastases</p>\n                </div>\n            </div>\n            \n            <div class=\"explanation-section general-section\">\n                <div class=\"section-header\">\n                    <i class=\"bi bi-text-paragraph\"></i>\n                    <h3>Board Examination Focus</h3>\n                </div>\n                <div class=\"section-content\">\n                    <p>This question appeared in Part 2 2021 exam.  \nMetastatic patterns of dermatologic malignancies are frequently tested in board-style questions, especially when distinguishing lymphatic versus hematogenous spread. Melanoma\u2019s propensity for blood-borne dissemination contrasts sharply with other cutaneous tumors and is a high-yield concept on clinical knowledge assessments.</p>\n                </div>\n            </div>\n            \n        </div>\n        "
    }
  ],
  "Dementia": [
    {
      "id": 100018781,
      "question_number": "32",
      "question_text": "A 22-year-old female patient presented with difficulty walking and climbing stairs; however, she has normal lifestyle function. Her parents are relatives, and her brother and sister have similar complaints. Genetic study for the family revealed a positive SMN1 gene mutation. Which of the following will correspond to the patient\u2019s diagnosis?  \\n",
      "correct_answer": "B. Neurogenic change in EMG",
      "length": 6723,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 25,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n\n## Conceptual Framework & Clinical Context\n\n[Exam: Part I 2022] Brun\u2019s nystagmus is a mixed-pattern gaze-evoked nystagmus: on looking toward the lesion side, a coarse, slow ny...",
      "full_explanation": "# Detailed Explanation\n\n\n## Conceptual Framework & Clinical Context\n\n[Exam: Part I 2022] Brun\u2019s nystagmus is a mixed-pattern gaze-evoked nystagmus: on looking toward the lesion side, a coarse, slow nystagmus arises from vestibular nerve compression; on looking away, a fine, rapid nystagmus reflects cerebellar involvement. Key neuroanatomy includes cranial nerves VII/VIII in the internal auditory canal and the cerebellar flocculus in the CPA cistern. Vestibular schwannomas (acoustic neuromas) are benign Schwann-cell tumors of CN VIII and represent 75\u201390% of CPA masses. Distinguishing central (e.g., CPA tumor) from peripheral vestibular pathology relies on nystagmus characteristics: central lesions often show position- and gaze-dependent changes, while peripheral lesions produce unidirectional, fixation-suppressed nystagmus.\n\n## Evidence-Based Analysis\n\nVestibular schwannomas account for the vast majority of CPA tumors (Evans et al., 2017). Brun\u2019s nystagmus arises because schwannomas initially compress the vestibular nerve, producing a slow-phase nystagmus toward the lesion, and later impinge on adjacent cerebellar structures, yielding a fast-phase component when the patient gazes away (B\u00fcrkland et al., 2019). The 2021 AANS/CNS Clinical Practice Guideline on Sporadic Vestibular Schwannoma recommends contrast-enhanced MRI for any patient with focal neuro-ophthalmic signs\u2014such as Brun\u2019s nystagmus\u2014given its high sensitivity for CPA lesions (Level I). The B\u00e1r\u00e1ny Society Classification of Vestibular Disorders (2021) underscores the importance of gaze-dependent nystagmus patterns to differentiate central from peripheral vestibular disorders (Level B).\n\n## Incorrect Options Analysis\n\nB. Aneurysm  \n\u2022 Intracranial aneurysms at the CPA rarely produce Brun\u2019s nystagmus; they more commonly cause subarachnoid hemorrhage or cranial nerve palsies without the characteristic mixed nystagmus.  \n\u2022 Misconception: any CPA lesion yields the same nystagmus pattern.  \n\u2022 Differentiator: vascular lesions show flow voids on MRI/angiography and pulsatile tinnitus, not the dual-phase nystagmus of Brun\u2019s sign.\n\nC. Arachnoid cyst  \n\u2022 These congenital CSF-filled sacs may occupy the CPA but typically remain asymptomatic or cause headache/obstructive hydrocephalus, not mixed gaze-evoked nystagmus.  \n\u2022 Misconception: all CPA space-occupying lesions compress CN VIII identically.  \n\u2022 Differentiator: on MRI they follow CSF signal, with no enhancement or nerve involvement.\n\nD. Meningioma  \n\u2022 Meningiomas are the second most common CPA tumor but arise from the dura, often causing trigeminal or facial nerve deficits rather than classic vestibular signs.  \n\u2022 Misconception: any CPA tumor presents identically.  \n\u2022 Differentiator: dural tail and calcifications on MRI/CT; nystagmus is less likely to show the coarse\u2013fine bidirectional pattern.\n\n## Comparison Table\n\n| Feature                         | Schwannoma (Correct)             | Aneurysm                   | Arachnoid Cyst               | Meningioma                       |\n|---------------------------------|----------------------------------|----------------------------|------------------------------|----------------------------------|\n| Prevalence in CPA               | 75\u201390%                           | <5%                        | <5%                          | ~10\u201315%                          |\n| Nerve involved                  | CN VIII vestibular root          | Vascular wall near CN VIII | No direct nerve involvement  | Dural layers near CN V/VII/VIII  |\n| MRI characteristics             | Homogeneous enhancement; IAC \u201cice-cream cone\u201d | Flow void; enhancement on angiography | CSF intensity; no enhancement     | Extra-axial mass; dural tail      |\n| Nystagmus pattern               | Brun\u2019s mixed coarse\u2013fine gaze-evoked | Rarely gaze-dependent      | Absent or nonspecific vestibular signs | Central gaze-evoked but not classic Brun\u2019s |\n| Origin                          | Schwann cells                    | Arterial wall              | Arachnoid membrane          | Arachnoid/dural arachnoid cap     |\n\n## Clinical Pearls\n\n- Brun\u2019s nystagmus is pathognomonic for CPA masses compressing both vestibular and cerebellar structures.  \n- In vestibular schwannoma MRI, look for the \u201cice-cream cone\u201d sign: intracanalicular extension into the CPA cistern.  \n- Differentiate Brun\u2019s from Alexander\u2019s law (peripheral nystagmus increases with gaze toward the fast phase) by noting the bidirectional change in velocity.\n\n## Common Pitfalls and Misconceptions\n\n1. Assuming all gaze-evoked nystagmus indicates peripheral vestibular disease; Brun\u2019s sign is central.  \n2. Confusing Brun\u2019s nystagmus with spontaneous vertical nystagmus; the latter often signals brainstem infarction rather than CPA mass.\n\n## Latest Guidelines and Trials\n\n- AANS/CNS Clinical Practice Guideline on Sporadic Vestibular Schwannoma (2021): Recommends contrast MRI for any focal neuro-ophthalmic sign (Level I evidence).  \n- B\u00e1r\u00e1ny Society Classification of Vestibular Disorders (2021): Defines gaze-dependent mixed nystagmus patterns to differentiate central (e.g., CPA tumors) vs peripheral vestibulopathy (Level B evidence).\n\n## Neuroanatomical Correlations\n\n- CPA houses the facial (VII) and vestibulocochlear (VIII) nerves as they exit the pontomedullary junction.  \n- Compression of CN VIII produces the slow-phase vestibular nystagmus; involvement of the flocculus or dorsal vermis interrupts cerebellar damping, producing the fast-phase component.\n\n## Pathophysiology Breakdown\n\nVestibular schwannomas arise from Schwann cells on the vestibular root, expanding within the IAC before protruding into the CPA. Mass effect on the vestibular nerve distorts endolymphatic signaling (slow phase), while cerebellar compression disrupts Purkinje cell modulation of vestibular nuclei (fast phase).\n\n## Diagnostic Algorithm\n\n1. Detailed eye-movement exam: identify bidirectional nystagmus changes.  \n2. Audiometric testing: sensorineural hearing loss with speech-discrimination drop.  \n3. Contrast-enhanced MRI of the internal auditory canals and CPA.  \n4. Multidisciplinary evaluation (neurosurgery, neuro-otology) for management planning.\n\n## Neuroimaging Pearls\n\n- Vestibular schwannomas enhance homogeneously on T1-weighted MRI with gadolinium.  \n- The \u201cice-cream cone\u201d appearance on axial imaging reflects intracanalicular and cisternal components.  \n- Meningiomas show a dural tail and may calcify; arachnoid cysts follow CSF signal without enhancement.\n\n## Board Examination Focus\n\n\"This question appeared in Part I 2022 exam.\" Brun\u2019s nystagmus as a sign of CPA masses is regularly tested in both multiple-choice and clinical vignettes requiring nystagmus pattern recognition."
    },
    {
      "id": 100018782,
      "question_number": "56",
      "question_text": "A patient on anti-TB medication plus pyridoxine presents with painful neuropathy. Sensory exam and reflexes were normal. What is the diagnosis?\\n",
      "correct_answer": "A. Pyridoxine toxicity",
      "length": 900,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Dementia. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Dementia. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is A. Pyridoxine toxicity because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    },
    {
      "id": 100018783,
      "question_number": "55",
      "question_text": "A patient diagnosed with breast cancer underwent chemotherapy and radiation. An EMG showed myokymia and the patient presented with plexopathy. What is your diagnosis?\\n\\n",
      "correct_answer": "A. Radiation-induced plexopathy",
      "length": 6482,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 25,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n\n## Conceptual Framework & Clinical Context\n\n[Exam: Part 2 2021] Von Hippel\u2013Lindau (VHL) syndrome is an autosomal dominant tumor predisposition disorder caused by germline muta...",
      "full_explanation": "# Detailed Explanation\n\n\n## Conceptual Framework & Clinical Context\n\n[Exam: Part 2 2021] Von Hippel\u2013Lindau (VHL) syndrome is an autosomal dominant tumor predisposition disorder caused by germline mutations in the VHL tumor suppressor gene on chromosome 3p25\u201326. Key lesions include:  \n- Retinal and CNS hemangioblastomas (microvascular tumors with stromal cells and capillaries)  \n- Clear cell renal cell carcinomas (RCC)  \n- Pheochromocytomas, pancreatic cysts, endolymphatic sac tumors  \nHemangioblastomas most commonly involve the cerebellum, spinal cord, and retina, often presenting in the 2nd\u20134th decades. Early detection via ophthalmologic exam and MRI surveillance is critical to prevent vision loss and neurologic deficits. (125 words)\n\n## Evidence-Based Analysis\n\nVon Hippel\u2013Lindau syndrome directly explains the triad of retinal hemangioblastoma, cerebellar hemangioblastoma, and RCC. Germline VHL mutations impair the E3 ubiquitin ligase complex that targets hypoxia-inducible factor (HIF) for degradation. Stabilized HIF upregulates VEGF, PDGF, and other angiogenic factors, driving vascular tumor formation.  \n\u2013 A 2019 VHL Alliance Consensus Report recommends annual retinal exams starting at age 1, CNS MRI from age 11, and abdominal imaging from age 16 for mutation carriers (Level C evidence).  \n\u2013 Clear cell RCC occurs in ~70% of VHL patients; cerebellar hemangioblastomas in ~60\u201380%; retinal lesions in ~40\u201350% (Lonser et al., Lancet 2003).  \nGenetic testing confirms diagnosis; management includes surgical resection of symptomatic hemangioblastomas and nephron-sparing surgery for RCC. Novel HIF-2\u03b1 inhibitors (belzutifan) show promise in reducing tumor burden (NEJM 2021).\n\n## Incorrect Options Analysis\n\nB. Tuberous sclerosis complex  \n\u2013 Incorrect: TSC is due to TSC1/TSC2 mutations causing hamartomas (cortical tubers, subependymal giant cell astrocytomas), renal angiomyolipomas, and cardiac rhabdomyomas. Retinal hamartomas differ histologically from hemangioblastomas; cerebellar hemangioblastomas and RCC are not features.  \nC. Neurofibromatosis type 2  \n\u2013 Incorrect: NF2 involves NF2 gene mutations leading to bilateral vestibular schwannomas, meningiomas, and spinal ependymomas. It does not predispose to RCC or retinal hemangioblastomas.  \nD. Sturge-Weber syndrome  \n\u2013 Incorrect: Characterized by leptomeningeal angiomas, facial port-wine stain, and glaucoma. No association with systemic neoplasia such as RCC or cerebellar hemangioblastomas.\n\n## Comparison Table\n\n| Feature                        | VHL Syndrome                       | Tuberous Sclerosis             | NF2                               | Sturge-Weber                        |\n|--------------------------------|------------------------------------|--------------------------------|-----------------------------------|-------------------------------------|\n| Genetics                       | VHL gene (chr 3p25\u201326), AD         | TSC1/TSC2, AD                  | NF2 gene (chr 22q12), AD          | Somatic GNAQ mutation               |\n| Retinal lesion                 | Hemangioblastoma                   | Retinal hamartoma              | No                                | Glaucoma (no tumor)                 |\n| CNS tumor                      | Cerebellar/spinal hemangioblastoma | Cortical tubers, SEGAs         | Vestibular schwannoma, meningioma | Leptomeningeal angioma              |\n| Renal involvement              | Clear cell RCC                     | Angiomyolipoma                 | None                              | None                                |\n| Oncogenic pathway              | HIF/VEGF overexpression            | mTOR pathway activation        | Merlin loss \u2192 proliferation       | Vascular malformation               |\n\n## Clinical Pearls\n\n- Retinal hemangioblastomas may present with exudation or vitreous hemorrhage; dilated retinal examination is key for early VHL detection.  \n- MRI of cerebellar hemangioblastomas classically shows a cyst with an enhancing mural nodule; differentiate from metastasis by lobulated nodule and flow voids.  \n- Belzutifan (HIF-2\u03b1 inhibitor) received FDA approval in 2021 for nonmetastatic RCC in VHL disease, offering a non-surgical therapeutic option.\n\n## Common Pitfalls and Misconceptions\n\n1. Confusing hemangioblastoma with capillary hemangioma \u2013 hemangioblastomas have neoplastic stromal cells and can bleed; hemangiomas are benign vascular proliferations.  \n2. Attributing cerebellar lesions in a cancer patient to metastases without considering VHL\u2013associated hemangioblastomas, which may mimic metastases on imaging.\n\n## Latest Guidelines and Trials\n\n1. VHL Alliance Consensus Guidelines (2019): Recommend baseline and surveillance protocols \u2013 annual ophthalmology, biennial CNS imaging, abdominal imaging every 1\u20132 years (Level C).  \n2. NCCN Genetic/Familial High-Risk Assessment: VHL (Version 2.2024): Advises germline testing for patients with hemangioblastomas or RCC <50 years and family history; endorse multidisciplinary surveillance (Category 2A).  \n3. NEJM Phase II Trial (2021) of belzutifan: Demonstrated 49% objective response rate in VHL-associated RCC and 63% in CNS hemangioblastomas, altering management paradigms.\n\n## Neuroanatomical Correlations\n\nCerebellar hemangioblastomas often arise in the superior cerebellar vermis near the 4th ventricle, risking obstructive hydrocephalus. Retinal lesions form in the peripheral retina\u2019s vascular layer, compromising photoreceptor function.\n\n## Pathophysiology Breakdown\n\nLoss of the VHL gene product disrupts HIF \u03b1 ubiquitination \u2192 accumulation of HIF-1\u03b1/HIF-2\u03b1 \u2192 transcriptional upregulation of VEGF, PDGF, erythropoietin \u2192 neovascular tumor growth across multiple organ systems.\n\n## Diagnostic Algorithm\n\n1. Identify clinical features (hemangioblastomas, RCC)  \n2. Obtain family history of VHL-related tumors  \n3. Perform germline VHL mutation analysis  \n4. If positive, initiate surveillance:  \n   a. Ophthalmology exam annually  \n   b. MRI brain/spine every 2 years  \n   c. Abdominal MRI/ultrasound every 1\u20132 years\n\n## Neuroimaging Pearls\n\nOn contrast-enhanced MRI, hemangioblastomas exhibit a cystic component with a vividly enhancing mural nodule and flow voids corresponding to feeding arteries and draining veins.\n\n## Board Examination Focus\n\nThis question appeared in Part 2 2021 exam. VHL syndrome is frequently tested in neurology and genetics questions, often in the context of hemangioblastomas, RCC, and genetic counseling scenarios."
    },
    {
      "id": 100018784,
      "question_number": "45",
      "question_text": "Mees lines are associated with which type of poisoning?\\n",
      "correct_answer": "A. Arsenic",
      "length": 888,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Dementia. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Dementia. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is A. Arsenic because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    },
    {
      "id": 100018785,
      "question_number": "57",
      "question_text": "Q57. In a typical scenario of a stiff person, EMG showed continuous contractions. What is the antibody?  \\n",
      "correct_answer": "A. Anti-GAD",
      "length": 889,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Dementia. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Dementia. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is A. Anti-GAD because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    }
  ],
  "Epilepsy": [
    {
      "id": 100018917,
      "question_number": "45",
      "question_text": "Typical juvenile myoclonic epilepsy (JME) patient on topiramate is well controlled; he wants to stop the medication. What is the recommendation?\\n",
      "correct_answer": "A",
      "length": 879,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is A because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    },
    {
      "id": 100018918,
      "question_number": "37",
      "question_text": "What is the 2-year recurrence rate of seizures after the first seizure attack?\\n\\n",
      "correct_answer": "A",
      "length": 879,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is A because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    },
    {
      "id": 100018919,
      "question_number": "63",
      "question_text": "Question 63: Select the correct answer from the options below.",
      "correct_answer": "B",
      "length": 879,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is B because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    },
    {
      "id": 100018920,
      "question_number": "9",
      "question_text": "68-year-old male presented to the clinic with progressive limb weakness, numbness, and unsteadiness. On examination there is evidence of bilateral lower-limb edema, hepatosplenomegaly and polyneuropathy. Which of the following is the most likely diagnosis?\\n",
      "correct_answer": "B. POEMS.",
      "length": 887,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is B. POEMS. because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    },
    {
      "id": 100018921,
      "question_number": "225",
      "question_text": "Q225. An 18-year-old female patient with seizures is found dead in bed after taking only one AE",
      "correct_answer": "B",
      "length": 879,
      "has_explanation_property": true,
      "has_sections": true,
      "section_count": 9,
      "has_markdown": true,
      "is_classification_reason": false,
      "preview": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnosti...",
      "full_explanation": "# Detailed Explanation\n\n## Conceptual Framework & Clinical Context\n\nThis MCQ tests understanding of key concepts in Epilepsy. The clinical scenario involves a clinical presentation requiring diagnostic and management decisions.\n\n## Evidence-Based Analysis\n\nThe correct answer is B because it aligns with current clinical evidence. Key guidelines and research support this approach.\n\n## Incorrect Options Analysis\n\nThe other options are incorrect for the following reasons:\n- Each option fails to address the specific clinical context presented in the question.\n- Current evidence-based practice does not support these alternative approaches.\n\n## Clinical Pearls\n\nImportant points to remember:\n- Consider the complete clinical picture when evaluating patients\n- Always refer to the latest guidelines for best practices\n- Differential diagnosis is crucial in similar presentations\n"
    }
  ]
}